didanosine ddi ddi sold brand name videx medication used treat used combination medications part highly active antiretroviral therapy haart reversetranscriptase inhibitor class didanosine first described approved use united states common adverse events didanosine diarrhea nausea vomiting abdominal pain fever headache peripheral neuropathy occurred participants key didanosine pancreatitis rarely observed caused occasional fatalities black box warning reported serious adverse events retinal changes optic neuritis alterations liver functions risk serious adverse events increased drinking alcohol february united states food drug administration issued statement patients using didanosine videx risk rare potentially fatal liver disorder noncirrhotic portal drug resistance didanosine develop though slower zidovudine zdv common mutation observed vivo viral pol gene confers crossresistance zalcitabine mutations observed include didanosine ddi nucleoside analogue differs nucleoside analogues regular bases instead hypoxanthine attached sugar ring within cell ddi phosphorylated active metabolite dideoxyadenosine triphosphate ddatp cellular enzymes like antihiv nucleoside analogs acts chain terminator incorporation inhibits viral reverse transcriptase competing natural datp oral absorption didanosine fairly low rapid food substantially reduces didanosine bioavailability drug administered empty halflife plasma intracellular environment hours entericcoated formulation marketed well elimination predominantly renal kidneys actively secrete didanosine amount oral dose related prodrug didanosine dda initially synthesized morris j robins professor organic chemistry brigham young university rk robins subsequently samuel broder hiroaki mitsuya robert yarchoan national cancer institute nci found dda ddi could inhibit hiv replication test tube conducted initial clinical trials showing didanosine activity patients infected hiv behalf nci awarded patents activities since nci market products directly national institutes health nih awarded tenyear exclusive license bristolmyers squibb co bms market sell ddi videx tablets didanosine became second drug approved treatment hiv infection many countries including united states food drug administration fda october fda approval helped bring price zidovudine zdv initial antihiv drug source needed pricing effect didanosine weak acid stability easily damaged stomach acid therefore original formula approved fda used chewable tablets included antacid buffering compound neutralize stomach acid chewable tablets large fragile also foultasting buffering compound would cause diarrhea although fda approved original formulation onceaday dosing possible people take way end tenyear license bms reformulated videx videx ec patented reformulation fda approved new formulation smaller capsule containing coated microspheres instead using buffering compound approved fda onceaday dosing also end tenyear period nih licensed didanosine barr laboratories nonexclusive license didanosine became first generic antihiv drug marketed united states one patents ddi expired united states august patents extend beyond time httpsenwikipediaorgwikididanosine